Email updates

Keep up to date with the latest news and content from BMC Medical Genetics and BioMed Central.

Open Access Highly Accessed Research article

A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death

Carolien H Teirlinck1, Faïza Senni1, Rajae El Malti1, Danielle Majoor-Krakauer2, Florence Fellmann3, Gilles Millat4, Xavier André-Fouët5, François Pernot6, Michaël Stumpf7, Jean Boutarin8 and Patrice Bouvagnet149*

Author Affiliations

1 Laboratoire cardiogénétique, Centre de Biologie et Pathologie Est, Groupe Hospitalier Est, 59 boulevard Pinel, Bron, Lyon, 69677, France

2 Department Clinical Genetics of Erasmus Medical Centre Rotterdam, Rotterdam, the Netherlands

3 Service de Génétique Médicale, CHUV, Lausanne, Switzerland

4 Service de Cardiologie Pédiatrique, Hospices Civils de Lyon, Lyon, France

5 Service de Cardiologie, Hospices Civils de Lyon, Lyon, France

6 Service de Médecine Nucléaire, Centre Hospitalier de Valence, Valence, France

7 Cabinet de Cardiologie, 31, rue Saint Maximin, Lyon, 69003, France

8 Service de Cardiologie, Hôpital Saint Joseph, Saint Luc, Lyon, France

9 EA 4173, Génomique fonctionnelle, Université de Lyon, Lyon, France

For all author emails, please log on.

BMC Medical Genetics 2012, 13:105  doi:10.1186/1471-2350-13-105

Published: 10 November 2012

Abstract

Background

Hypertrophic Cardiomyopathy (HCM) is a genetically heterogeneous disease. One specific mutation in the MYBPC3 gene is highly prevalent in center east of France giving an opportunity to define the clinical profile of this specific mutation.

Methods

HCM probands were screened for mutation in the MYH7, MYBPC3, TNNT2 and TNNI3 genes. Carriers of the MYBPC3 IVS20-2A>G mutation were genotyped with 8 microsatellites flanking this gene. The age of this MYBPC3 mutation was inferred with the software ESTIAGE. The age at first symptom, diagnosis, first complication, first severe complication and the rate of sudden death were compared between carriers of the IVS20-2 mutation (group A) and carriers of all other mutations (group B) using time to event curves and log rank test.

Results

Out of 107 HCM probands, 45 had a single heterozygous mutation in one of the 4 tested sarcomeric genes including 9 patients with the MYBPC3 IVS20-2A>G mutation. The IVS20-2 mutation in these 9 patients and their 25 mutation carrier relatives was embedded in a common haplotype defined after genotyping 4 polymorphic markers on each side of the MYBPC3 gene. This result supports the hypothesis of a common ancestor. Furthermore, we evaluated that the mutation occurred about 47 generations ago, approximately at the 10th century.

We then compared the clinical profile of the IVS20-2 mutation carriers (group A) and the carriers of all other mutations (group B). Age at onset of symptoms was similar in the 34 group A cases and the 73 group B cases but group A cases were diagnosed on average 15 years later (log rank test p = 0.022). Age of first complication and first severe complication was delayed in group A vs group B cases but the prevalence of sudden death and age at death was similar in both groups.

Conclusion

A founder mutation arising at about the 10th century in the MYBPC3 gene accounts for 8.4% of all HCM in center east France and results in a cardiomyopathy starting late and evolving slowly but with an apparent risk of sudden death similar to other sarcomeric mutations.

Keywords:
Hypertrophic cardiomyopathy; MYBPC3; Mutation; Founder effect